Methods and compositions for use with k-ras mediated disorders
AssigneeBoard of Regents, The University of Texas System
InventorsJohn F. HANCOCK, Dharini VAN DER HOEVEN, Kwang-Jin CHO
Life of this patent
Estimating the term…
Abstract
Methods and compositions that can be used to identify and characterize inhibitors of K-ras localization to the plasma membrane and in doing so inhibit the signal transduction of K-ras. Such compositions can be used to treat K-ras mediated disorders, such as cancer.
Claims20
A method of inhibiting K-ras signaling;
- wherein said inhibiting comprises:
- blocking the association of a K-ras protein with a plasma membrane, wherein said blocking is by a chemical compound.
A method of treating a K-ras mediated disorder in a patient in need thereof;
- said method comprising:
- administering to the patient a therapeutically effective amount of a compound that inhibits K-ras signaling by blocking the association of the K-ras protein with plasma membrane.
A method of identifying a compound that blocks the association of K-ras protein with a plasma membrane;
- the method comprising:
- a) incubating MDCK-GFP-Target cells constructs;
- b) adding a test compound to said cells, and further incubating;
- c) imaging cells from step b);
- d) analyzing protein localization in cells of step c;
- and
- e) selecting based on step d) compounds that block protein localization compared to a control, wherein said compounds inhibit K-ras signaling
A medicament comprising a therapeutically effective amount of fendiline or fendiline HCl or a combination thereof, to inhibit K-ras signaling to treat a K-ras mediated disorder in a patient in need of such a treatment.
Dependencies are inferred from the claim text.